Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Gallbladder Neoplasms × Observation × 1 year × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 9 Prostatic Neoplasms 8 Carcinoma, Non-Small-Cell Lung 8 Endometrial Neoplasms 7 Lung Neoplasms 6 Breast Neoplasms 6 Colorectal Neoplasms 5 Oropharyngeal Neoplasms 4 Stomach Neoplasms 3 Rectal Neoplasms 3 Pancreatic Neoplasms 3 Neoplasm Metastasis 3 Mouth Neoplasms 3 Leukemia, Myeloid, Acute 3 Colonic Neoplasms 3 Urinary Bladder Neoplasms 2 Skin Neoplasms 2 Sarcoma 2 Pathologic Complete Response 2 Meningioma 2 Melanoma 2 Lymphoma, Large B-Cell, Diffuse 2 Leukemia 2 Leiomyoma 2 Esophageal Neoplasms 2 Carcinoma, Intraductal, Noninfiltrating 2 Brain Neoplasms 2 Bone Neoplasms 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1

Interventions

Gemcitabine 15 Cisplatin 15 pembrolizumab 9 durvalumab 7 Oxaliplatin 7 130-nm albumin-bound paclitaxel 6 Capecitabine 5 Leucovorin 4 Fluorouracil 4 Trastuzumab 3 Albumin-Bound Paclitaxel 3 zanidatamab 2 anlotinib 2 Taxes 2 S 1 (combination) 2 Platinum 2 Paclitaxel 2 Nivolumab 2 Magnetic Resonance Spectroscopy 2 Folfox protocol 2 Docetaxel 2 1,2-diaminocyclohexaneplatinum II citrate 2 tucatinib 1 trifluridine tipiracil drug combination 1 tremelimumab 1 trastuzumab deruxtecan 1 tivozanib 1 seribantumab 1 pertuzumab 1 lenvatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06192719 2026-02-18

EULAT

Centre Paul Strauss

15,000 enrolled

Gastrointestinal

Cholelithiasis, Gallbladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡